- Home
- Publications
- Publication Search
- Publication Details
Title
PPAR Agonists and Metabolic Syndrome: An Established Role?
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 19, Issue 4, Pages 1197
Publisher
MDPI AG
Online
2018-04-16
DOI
10.3390/ijms19041197
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Is It Time for New Thinking About High-Density Lipoprotein?
- (2018) Christian M. Madsen et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
- (2018) Eiichi Araki et al. DIABETES CARE
- Update on the Impact of Omega 3 Fatty Acids on Inflammation, Insulin Resistance and Sarcopenia: A Review
- (2018) et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders
- (2018) Xavier Palomer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
- (2018) Hidenori Arai et al. Journal of Atherosclerosis and Thrombosis
- Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial
- (2018) Erik S.G. Stroes et al. Journal of Clinical Lipidology
- Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials
- (2018) Amirhossein Sahebkar et al. Journal of Clinical Lipidology
- Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
- (2018) Shun Ishibashi et al. Journal of Clinical Lipidology
- Omega-3 fatty acids and adipose tissue biology
- (2018) Ondrej Kuda et al. MOLECULAR ASPECTS OF MEDICINE
- Effect of fibrates on glycemic parameters: A systematic review and meta-analysis of randomized placebo-controlled trials
- (2018) Luis E. Simental-Mendía et al. PHARMACOLOGICAL RESEARCH
- Present therapeutic role of cholesteryl ester transfer protein inhibitors
- (2018) Nicola Ferri et al. PHARMACOLOGICAL RESEARCH
- Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks
- (2018) Theingi Aung et al. JAMA Cardiology
- Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study
- (2017) Christian M Madsen et al. EUROPEAN HEART JOURNAL
- PPAR-α agonists are still on the rise: an update on clinical and experimental findings
- (2017) Nicola Ferri et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Distinct but complementary contributions of PPAR isotypes to energy homeostasis
- (2017) Vanessa Dubois et al. JOURNAL OF CLINICAL INVESTIGATION
- Adipose tissue inflammation in insulin resistance: review of mechanisms mediating anti-inflammatory effects of omega-3 polyunsaturated fatty acids
- (2017) Mandana Pahlavani et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
- (2017) Anna M. Diehl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions
- (2017) M. Ruscica et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Non-insulin anti-diabetic drugs: An update on pharmacological interactions
- (2017) M. Ruscica et al. PHARMACOLOGICAL RESEARCH
- The Role of Omega-3 Fatty Acids in Reverse Cholesterol Transport: A Review
- (2017) Alex Pizzini et al. Nutrients
- Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
- (2017) Marshall B. Elam et al. JAMA Cardiology
- Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products
- (2016) Jonathan Fialkow American Journal of Cardiovascular Drugs
- Prevalence of metabolic syndrome in mainland china: a meta-analysis of published studies
- (2016) Ri Li et al. BMC PUBLIC HEALTH
- Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
- (2016) Changting Xiao et al. DIABETES
- Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease
- (2016) Silvio E. Inzucchi et al. DIABETES CARE
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
- (2016) Yaron Rotman et al. GUT
- Pioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial
- (2016) Catherine M. Viscoli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- (2016) Walter N. Kernan et al. NEW ENGLAND JOURNAL OF MEDICINE
- PPARγ signaling and emerging opportunities for improved therapeutics
- (2016) Shuibang Wang et al. PHARMACOLOGICAL RESEARCH
- Brown but not white adipose cells synthesize omega-3 docosahexaenoic acid in culture
- (2016) Xia Qin et al. PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
- The lipid sensor GPR120 promotes brown fat activation and FGF21 release from adipocytes
- (2016) Tania Quesada-López et al. Nature Communications
- Molecular Mechanisms of PPAR-γ; Governing MSC Osteogenic and Adipogenic Differentiation
- (2016) Haoliang Zhuang et al. Current Stem Cell Research & Therapy
- PPAR-delta promotes survival of breast cancer cells in harsh metabolic conditions
- (2016) X Wang et al. Oncogenesis
- Lack of Sterol Regulatory Element Binding Factor-1c Imposes Glial Fatty Acid Utilization Leading to Peripheral Neuropathy
- (2015) Gaia Cermenati et al. Cell Metabolism
- History and future of omega-3 fatty acids in cardiovascular disease
- (2015) Laurence S. Sperling et al. CURRENT MEDICAL RESEARCH AND OPINION
- Acetyl-CoA and the regulation of metabolism: mechanisms and consequences
- (2015) Lei Shi et al. CURRENT OPINION IN CELL BIOLOGY
- Risk identification and possible countermeasures for muscle adverse effects during statin therapy
- (2015) Paolo Magni et al. European Journal of Internal Medicine
- Mice fed fish oil diet and upregulation of brown adipose tissue thermogenic markers
- (2015) Thereza Cristina Lonzetti Bargut et al. EUROPEAN JOURNAL OF NUTRITION
- Prevalence of the Metabolic Syndrome in the United States, 2003-2012
- (2015) Maria Aguilar et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver
- (2015) Sana Raza-Iqbal et al. Journal of Atherosclerosis and Thrombosis
- Fish-Oil–Derived n–3 PUFAs Reduce Inflammatory and Chemotactic Adipokine-Mediated Cross-talk between Co-cultured Murine Splenic CD8+ T Cells and Adipocytes
- (2015) Jennifer M Monk et al. JOURNAL OF NUTRITION
- Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome
- (2015) Harold E. Bays et al. Metabolic Syndrome and Related Disorders
- Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes
- (2015) Sanjay Chatterjee et al. Scientific Reports
- New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease
- (2014) Amirhossein Sahebkar et al. EXPERT OPINION ON PHARMACOTHERAPY
- PPARs Integrate the Mammalian Clock and Energy Metabolism
- (2014) Lihong Chen et al. PPAR Research
- Integrated physiology and systems biology of PPARα
- (2014) Sander Kersten Molecular Metabolism
- Prevalence of metabolic syndrome in Brazilian adults: a systematic review
- (2013) Fernanda de Carvalho Vidigal et al. BMC PUBLIC HEALTH
- A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial)
- (2013) Kevin C. Maki et al. CLINICAL THERAPEUTICS
- A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)
- (2013) Rajendrakumar H. Jani et al. Diabetes Technology & Therapeutics
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia
- (2013) Angela Pirillo et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial
- (2013) John J.P. Kastelein et al. Journal of Clinical Lipidology
- Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
- (2012) Alexander Tenenbaum et al. Cardiovascular Diabetology
- Examining the safety of PPAR agonists – current trends and future prospects
- (2012) Michele Bortolini et al. Expert Opinion On Drug Safety
- The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function
- (2012) Elizabeth Gray et al. Journal of Neuroinflammation
- Mechanisms of Action of (n-3) Fatty Acids
- (2012) Philip C. Calder JOURNAL OF NUTRITION
- PPARs at the crossroads of lipid signaling and inflammation
- (2012) Walter Wahli et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis
- (2011) Melissa Y. Wei et al. Current Atherosclerosis Reports
- Effects of the New Dual PPAR / Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
- (2011) B. Cariou et al. DIABETES CARE
- Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice
- (2011) Jiansheng Huang et al. FASEB JOURNAL
- Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients
- (2011) Stephen J. Nicholls et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Peroxisome Proliferator-Activated Receptor δ Regulates Inflammation via NF-κB Signaling in Polymicrobial Sepsis
- (2010) Basilia Zingarelli et al. AMERICAN JOURNAL OF PATHOLOGY
- Rosiglitazone Revisited
- (2010) Steven E. Nissen et al. ARCHIVES OF INTERNAL MEDICINE
- PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice
- (2010) Anna Foryst-Ludwig et al. Cardiovascular Diabetology
- GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects
- (2010) Da Young Oh et al. CELL
- PPARγ in adipocyte differentiation and metabolism - Novel insights from genome-wide studies
- (2010) Rasmus Siersbaek et al. FEBS LETTERS
- Cell-Specific Determinants of Peroxisome Proliferator-Activated Receptor Function in Adipocytes and Macrophages
- (2010) M. I. Lefterova et al. MOLECULAR AND CELLULAR BIOLOGY
- n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
- (2010) Daan Kromhout et al. NEW ENGLAND JOURNAL OF MEDICINE
- Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk
- (2010) M. John Chapman et al. PHARMACOLOGY & THERAPEUTICS
- Harmonizing the Metabolic Syndrome
- (2009) K.G.M.M. Alberti et al. CIRCULATION
- Antidiabetic Action of Bezafibrate in a Large Observational Database
- (2009) J. H. Flory et al. DIABETES CARE
- CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone
- (2009) D. John Betteridge FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Fenofibrate Simultaneously Induces Hepatic Fatty Acid Oxidation, Synthesis, and Elongation in Mice
- (2009) Maaike H. Oosterveer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus
- (2008) Michael Davidson et al. CIRCULATION
- PPAR and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale
- (2008) M. I. Lefterova et al. GENES & DEVELOPMENT
- Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Suppression of Pro-inflammatory Adhesion Molecules by PPAR-δ in Human Vascular Endothelial Cells
- (2007) Yanbo Fan et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More